Business Context and Reporting Period
This Form 8-K Current Report was filed by Rocket Pharmaceuticals, Inc. (RCKT) on April 22, 2020, covering events occurring on April 20, 2020. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in New York, NY.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors:
- Appointment: Elisabeth Björk, M.D., Ph.D., was appointed to the Board effective April 20, 2020.
- Committee Assignment: Dr. Björk was appointed to the Audit Committee.
- Compensation: Dr. Björk was granted an option to purchase 40,000 shares of common stock at the closing market price on the grant date.
- Vesting Schedule: Options vest over three years (one-third after one year; remaining two-thirds in equal monthly installments over the subsequent two years), contingent on continued service.
Management Commentary and Background
Management highlighted Dr. Björk's extensive experience in the pharmaceutical industry, specifically her role as Senior Vice President, Head of Late-Stage Development, Cardiovascular, Renal and Metabolism at AstraZeneca. She brings 15 years of clinical practice and diabetes research experience from Uppsala University and over 18 years of experience at AstraZeneca. The Board cited her depth of knowledge in drug development as a key qualification.
The filing confirms there are no family relationships between Dr. Björk and other directors or officers, and no related person transactions exist.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 40,000 stock options granted to Dr. Björk.
- Confirm Dr. Björk's current status on the Board and Audit Committee in subsequent filings.
- Review the Company's non-employee director compensation policy for context on the grant size relative to other directors.
- Check for any potential conflicts of interest given Dr. Björk's concurrent employment at AstraZeneca.